Canada approved Amylyx Pharmaceuticals Inc.’s new drug for amyotrophic lateral sclerosis last week. Now some U.S. patients with the fatal neurodegenerative disorder—also known as Lou Gehrig’s disease—are considering a trip north to get the medication, Albrioza. The drug isn’t approved in the U.S.
William Woods, a 75-year-old retired doctor in Atlanta who was diagnosed with ALS in 2019, is contacting Canadian doctors who might help him get Albrioza. “There is a lot to figure out,” he said, “but I am confident I will find somebody I can go see.”
